Literature DB >> 22193216

Reevaluation of predictive value of ACL and anti-β2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world.

Xiaoli Deng1, Xiangyuan Liu.   

Abstract

Detection of ACL (anticardiolipin, ACL) and anti-β2GP1 (beta2 glycoprotein1, β2GP1) antibody has been widely used, and the criteria of APS (Antiphospholipid syndrome, APS) have been used for the prediction of thrombosis in patients with SLE. What is the exact predictive value of these two antibodies? Is it really necessary to apply the criteria of APS to each patient just for the purpose of prediction of thrombosis? The aim of this retrospective study is to reevaluate the predictive value of different combination of ACL and anti-β2GP1 antibody for thrombosis formation in Chinese patients with SLE. Patients fulfilling the 1997 ACR classification criteria for SLE were enrolled and retrospectively analyzed. Thrombosis was confirmed by ultrasound, cerebral MRI, computed tomography pulmonary angiogram and angiography. Both IgG and IgM isotype of ACL and anti-β2GP1 antibody were detected with ELISA kit. ROC curves and other parameters of diagnostic test for different combination of ACL and anti-β2GP1 were analyzed and compared. 175 patients were recruited and thrombosis was diagnosed in 49 patients. In patients with thrombosis, 95.9% had been treated with glucocorticoids before detection of the two antibodies, 44.9% had hypertension and 53.1% had hyperlipidemia. ACL was positive in 28 patients (16%), and anti-β2GP1 antibody was positive in 21 patients (12%). The presence of a low or higher titer of either ACL (>12 RU/ml) or anti-β2GP1 antibody (>20 RU/ml) once has the highest predictive accuracy. The sensitivity, the specificity, the Youden's index and the area under ROC curve are 61.11%, 81.11%, 0.4222 and 0.711 respectively. A transient low or higher titer of ACL or anti-β2GP1 antibody had a good predictive value for thrombosis in patients with SLE, especially in those with other traditional risk factors for thrombosis and those treated with glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193216     DOI: 10.1007/s00296-011-2267-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

Review 1.  Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome.

Authors:  Monica Galli; Davide Luciani; Guido Bertolini; Tiziano Barbui
Journal:  Blood       Date:  2003-06-19       Impact factor: 22.113

2.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus.

Authors:  Christoph Male; Denise Foulon; Hugh Hoogendoorn; Patricia Vegh; Earl Silverman; Michèle David; Lesley Mitchell
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

Review 5.  Anti-beta2-glycoprotein I antibodies--when and how should they be measured?

Authors:  Guido Reber; Philippe de Moerloose
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

Review 6.  [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].

Authors:  P Sarzi-Puttini; F Atzeni; M Carrabba
Journal:  Minerva Med       Date:  2003-04       Impact factor: 4.806

7.  Antibodies to phospholipids and nuclear antigens in non-pregnant women with unexplained spontaneous recurrent abortions.

Authors:  A M Bahar; J Y Kwak; A E Beer; J H Kim; L A Nelson; K D Beaman; A Gilman-Sachs
Journal:  J Reprod Immunol       Date:  1993-08       Impact factor: 4.054

8.  Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women.

Authors:  P L Meroni; F Peyvandi; L Foco; L Bernardinelli; R Fetiveau; P M Mannucci; A Tincani
Journal:  J Thromb Haemost       Date:  2007-12       Impact factor: 5.824

9.  Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

Authors:  R Cervera; M A Khamashta; J Font; G D Sebastiani; A Gil; P Lavilla; I Doménech; A O Aydintug; A Jedryka-Góral; E de Ramón
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

10.  Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.

Authors:  Tunde Tarr; Gabriella Lakos; Harjit Pal Bhattoa; Pal Soltesz; Yehuda Shoenfeld; Gyula Szegedi; Emese Kiss
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

View more
  2 in total

1.  Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.

Authors:  Koji Habe; Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Makoto Ikejiri; Kimiko Matsubara; Tatsuhiko Morioka; Yuki Kamimoto; Tomoaki Ikeda; Naoyuki Katayama; Tsutomu Nobori; Hitoshi Mizutani
Journal:  Int J Hematol       Date:  2013-02-03       Impact factor: 2.490

2.  Vascular disease in systemic lupus erythematosus.

Authors:  Athina Pyrpasopoulou; Sofia Chatzimichailidou; Spyros Aslanidis
Journal:  Autoimmune Dis       Date:  2012-08-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.